,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'destiny-04', 'breast', 'bcsm']
listen in as , executive vice president of , and , vice president for clinical research at , discuss what the results of destiny-04 mean for breast cancer care. #bcsm #asco22 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.